Anlotinib 3 (Chart 1) is an oral, selective VEGFR2 inhibitor with significantly fewer side effects than 1 [38], approved in China for the therapeutic treatment of patients with non-small cell lung cancer (NSCLC) [39]. The gene discussed is KDR; the disease is non-small cell lung carcinoma.